Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 5 FG
Devotta A et al. (2023)
|
Xla wt + A71915 (npr1 antagonist)
NF25 (in situ hybridization)
|
|
|
|
Fig. 2 FG
Devotta A et al. (2023)
|
Xla wt + AP-811 (npr3 antagonist)
NF25 (in situ hybridization)
|
|
|
|
Fig. 2. U, V
Mishra-Gorur K et al. (2023)
|
Xtr Wt + traf1
NF17 (in situ hybridization)
|
|
|
|
Fig. 2. O
Mishra-Gorur K et al. (2023)
|
Xtr wt + traf7 MO
NF16-18 (in situ hybridization)
|
|
|
|
Fig. 5A
Job F et al. (2023)
|
Xla Wt + otud3 MO
NF20 (in situ hybridization)
|
|
|
|
Fig. 4 B r1c4
Herchenröther A et al. (2023)
|
Xla Wt + hmg20a MO
NF26-28 (in situ hybridization)
|
|
|
No Image
|
Fig. 5C
Flach H et al. (2022)
|
Xla Wt + glyphosate [243]
NF23 (in situ hybridization)
|
|
|
|
Fig. 3A
Delhermite J et al. (2022)
|
Xla Wt + fbl MO
NF15-18 (in situ hybridization)
|
|
|
|
Fig. 3A
Delhermite J et al. (2022)
|
Xla Wt + fbl MO
NF32 (in situ hybridization)
|
|
|
|
Fig. 3 a row1
Ihewulezi C and Saint-Jeannet JP (2021)
|
Xla Wt + hmgn1 MO
NF15 (in situ hybridization)
|
|
|